Beyond Achondroplasia

Growing together with Clara

Rare diseases and orphan drugs market

July 11, 2014 by inesp.alves | 0 comments


March 3, 2014
by inesp.alves

Orphan drugs summit 2014 – Copenhagen, 17th – 19th September

This September, it will be discussed crucial topics around orphan drugs. Far beyond the scientific studies, laboratory development of the drugs, the clinical trials, all the permissions needed from FDA, EMA and other drug regulators,before getting the drug in the market and the … Continue reading

September 10, 2013
by inesp.alves

Meclozine – can this be a new chance for achondroplasia treatment?

A group of Japanese researchers  presented in ISDS Meeting Bologna 2013, the following study: Meclozine facilitates chondrocyte proliferation and differentiation by attenuating abnormally activated fibroblast growth factor receptor 3 (FGFR3) signaling in achondroplasia. Achondroplasia (ACH) is one of the most … Continue reading

Translate »